Immunogenicity of 13-valent pneumococcal conjugate vaccine in immunocompetent older adults with stable underlying medical conditions

Schmöele-Thoma, Beate; LA, Jackson; RN, Greenberg; Frenck, R; Gurtman, A; Sundaraiyer, V; WC, Gruber; DA, Scott; RE, Isturiz

doi:10.14312/2053-1273.2015-2

Cited by 6 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vaccine efficacy was 30.6% against pneumococcal CAP and 75% against VT-IPD. Furthermore, the magnitude and duration of humoral immune responses in adult at-risk subjects assessed by opsonophagocytic tests and the geometric mean antibody titers were comparable to those of the overall population and persisted for at least 2 years [84]. A post hoc analysis predicted that vaccine efficacy could drop from 65% for 65-year-old adults to 40% for 75-year-old adults.…”

Section: Immunological Features: the Immune Response To The Vaccinementioning

confidence: 83%

Pneumonia and Invasive Pneumococcal Diseases: The Role of Pneumococcal Conjugate Vaccine in the Era of Multi-Drug Resistance

et al. 2021

View full text Add to dashboard Cite

Streptococcus pneumoniae related diseases are a leading cause of morbidity and mortality, especially in children and in the elderly population. It is transmitted to other individuals through droplets and it can spread to other parts of the human host, causing a wide spectrum of clinical syndromes, affecting between 10 and 100 cases per 100,000 people in Europe and the USA. In order to reduce morbidity and mortality caused by this agent, pneumococcal vaccines have been developed over the years and have shown incredible effectiveness in reducing the spread of this bacterium and the development of related diseases, obtaining a significant reduction in mortality, especially in developing countries. However, considerable problems are emerging mainly due to the replacement phenomenon, multi-drug resistance, and the high production costs of conjugated vaccines. There is still a debate about the indications given by various countries to different age groups; this is one of the reasons for the diffusion of different serotypes. To cope with these problems, significant efforts have been made in the research field to further improve vaccination serotypes coverage. On the other hand, an equally important commitment by health care systems to all age group populations is needed to improve vaccination coverage.

show abstract

Section: Immunological Features: the Immune Response To The Vaccinementioning

confidence: 83%